Medical Research

Sickle Cell Disease/Advancing Cures Frequently Asked Questions

Jump to FAQ's about: Budget & Financials, Other Sources of Funding, IRB/IND Requirements and Miscellaneous

If your question is not answered after reviewing the FAQs, email ddcf@aibs.org with “SCD/AC” as the subject line. No phone calls, please. We are better able to address your questions if contacted via email and cannot guarantee that all phone calls will be immediately answered.

Budget & Financials

What are allowable grant costs?

For general guidance about allowable grant costs, please check our grantee Guidelines and Policies. For specific questions, please read the Request for Applications or inquire at ddcf@aibs.org with “SCD/AC.”

Do I need to list co-investigators in the budget even if their effort will not be charged to the Sickle Cell Disease/Advancing Cures grant?

Yes. Co-investigators and their effort towards the proposed Sickle Cell Disease/Advancing Cures project should be specified in the budget even if salary charges are not planned.

Does the award support indirect costs?

Yes. The three-year award is inclusive of indirect costs at a rate of 10 percent.

I plan on establishing subcontracts with investigators at other institutions to carry out the Sickle Cell Disease/Advancing Cures project. Can these investigators charge indirect costs in the sub-contract?

Yes. Subcontracts may charge indirect costs at a rate of up to 10 percent of the subcontract direct cost.

If the budget has a sub-contract, do I include the sub-contract total cost in the main budget's 10 percent indirect cost calculation?

No. Do not include the total subcontract cost in the main budget’s indirect cost calculation. Please use our budget template to avoid subcontract costs being double-counted in budget calculations. Please simply follow the numerical formulations in the budget template. (The subcontract indirect costs will come out of the resulting total annual indirect cost amount.)

Is there a salary cap for this award?

No. The foundation does not have a salary cap for this award. However, the amount of salary charged to the grant must be commensurate with the effort that will be dedicated to the research project.

Other Sources of Funding

What is the foundation’s policy regarding other sources of funding?

There can be no scientific or budgetary overlap between the proposed aims of the Sickle Cell Disease/Advancing Cures research and those of other awards, either at the time of application or after the DDCF award has been made.

Institutional Review Board/Investigational New Drug Requirements

When is Institutional Review Board approval or submission required to be in effect,—at the time of the full proposal submission or before an award is made?

Institutional Review Board (IRB) approval, if necessary, is not required at the time of proposal submission. However, if a grant is awarded, DDCF strongly prefers IRB approval to be in place by the grant start date of September 1, 2017 and no later than December 1, 2017.

When is Investigational New Drug (IND) approval required to be in effect—at the time of the full proposal submission or before an award is made?

If necessary, Investigational New Drug approval must be in place by the application submission deadline of May 25, 2017. Exceptions may be considered on a case-by-case basis. Please contact the foundation at ddcf@aibs.org ahead of the deadline and before making an application submission. Please include “SCD/AC” in the subject line.

Miscellaneous

What is DDCF's definition of clinical research?

Clinical research involves the scientific investigation of the etiology, prevention, diagnosis or treatment of human disease using human subjects, human populations or materials of human origin. DDCF’s definition also includes studies that utilize tissues or pathogens only if they can be linked to a patient.

It is expected that the research protocols of grant applicants will require Institutional Review Board (IRB) approval. Occasionally, the foundation has funded research that does not require IRB approval, such as research using de-identified patient populations. If a research project is being proposed that does not require IRB approval, applicants are strongly encouraged to contact program staff to discuss whether the proposed research falls within the DDCF's definition of clinical research.

In keeping with the wishes expressed in Doris Duke’s will, experiments that use animals or primary tissues derived from animals will not be supported by this program.

What is the success rate for applicants submitting proposals?

There is no way to definitively know how many proposals we will receive this year, and therefore what the success rate will be. However, based on data from previous Medical Research Program competitions, we estimate an award rate of 10 percent.

How many awards will be made?

DDCF has committed approximately $5,000,000 to the Sickle Cell Disease/Advancing Cures program, which amounts to about eight 3-year grants starting in 2017. However, this may vary based on both the quality of the applications received and the proposed budget of meritorious applications.

What is DDCF’s public access policy for publications funded through its grants?

For this program, DDCF’s requires grantees to submit an electronic copy of their final peer‐reviewed manuscripts in the PubMed Central online archive immediately upon acceptance for journal publication. The manuscript will have to be made publicly available in PubMed Central no later than 12 months after the official date of journal publication.

Would the public access policy adopted by DDCF limit the journals to which grantees can submit their DDCF-funded work?

No. Grantees may publish their work in any journal they wish. However, the final accepted manuscript must be deposited in PubMed Central for public release no longer than 12 months after acceptance for publication.